Annovis Bio CEO Participates in Roundtable Discussion at the Financial Times’ Outstanding Directors Exchange and Panel Disc...
October 20 2020 - 6:45AM
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug
platform company addressing Alzheimer’s disease (AD), Parkinson’s
disease (PD) and other neurodegenerative diseases, today announced
its Founder and Chief Executive Officer, Maria Maccecchini, Ph.D.,
will participate in the Financial Times’ Outstanding Director
Exchange (ODX) Roundtable: The Evolving Relationship Between Pharma
and Biotech on Tuesday, October 20, 2020 at 11:40 a.m. ET.
The ODX conference is now in its 16th year and
continues to be the gold standard for director education and
community. Attendance is limited exclusively to
sitting public company directors.
In addition, Dr. Maccecchini will participate in
the Angel Venture Fair Women’s Founders and Funders panel
discussion on October 20, 2020 at 8:15 a.m. ET. Angel Venture Fair,
a non-profit consortium of accredited investors and angel investor
groups, brings together the largest gathering of angel, seed, and
early-stage investors in the Mid-Atlantic region.
“I am excited to share my experiences on both of
these subjects with the director community and with aspiring women
entrepreneurs,” continued Dr. Maccecchini. “I have been working
with small companies as a CEO, director and angel investor since
1992. With deep experience as an investor and entrepreneur, I
believe I can provide valuable insight that attendees at both
events can apply on their paths to success.”
About Annovis Bio
Headquartered in Berwyn, Pennsylvania, Annovis
Bio, Inc. (Annovis) is a clinical-stage, drug platform company
addressing neurodegeneration, such as Alzheimer’s disease (AD),
Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
We believe that we are the only company developing a drug for AD,
PD and AD-DS that inhibits more than one neurotoxic protein and,
thereby, improves the information highway of the nerve cell, known
as axonal transport. When this information flow is impaired, the
nerve cell gets sick and dies. We expect our treatment to improve
memory loss and dementia associated with AD and AD-DS, as well as
body and brain function in PD. We have an ongoing Phase 2a study in
AD patients and have commenced a second Phase 2a study in AD and PD
patients. For more information on Annovis, please visit the
company’s website: www.annovisbio.com.
Forward-Looking Statements
Statements in this press release contain
“forward-looking statements” that are subject to substantial risks
and uncertainties. Forward-looking statements contained in this
press release may be identified by the use of words such as
“anticipate,” “expect,” “believe,” “will,” “may,” “should,”
“estimate,” “project,” “outlook,” “forecast” or other similar
words, and include, without limitation, statements regarding the
timing, effectiveness and anticipated results of ANVS401 clinical
trials. Forward-looking statements are based on Annovis Bio, Inc.’s
current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. Further,
certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate, including that
clinical trials may be delayed. These and other risks and
uncertainties are described more fully in the section titled “Risk
Factors” in the Annual Report on Form 10-K for the year ended
December 31, 2019 filed with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date, and Annovis Bio, Inc.
undertakes no duty to update such information except as required
under applicable law.
Investor Relations:Dave Gentry, CEORedChip Companies
Inc.407-491-4498Dave@redchip.com
SOURCE: Annovis Bio, Inc.
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Apr 2024 to May 2024
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From May 2023 to May 2024